Renaissance Investment Management added a new position in Zoetis Inc. to its Large Cap Growth Strategy during the first quarter of 2026. The firm cited Zoetis's position as the global leader in vaccines and pharmaceuticals for companion animals and livestock, and expects revenue to reaccelerate as COVID-era pets reach ages requiring preventive treatments. Renaissance also highlighted the company's new drug pipeline targeting cancer, kidney, heart, obesity, and anxiety over the next four years, along with rising protein demand and a pain medication relaunch. Zoetis shares closed at $79.33 on June 16, 2026, with a market capitalization of $33.25 billion, and have fallen 48.57% over the past 52 weeks.
Zoetis IncRenaissance added Zoetis to its portfolio, citing expected revenue reacceleration from aging COVID-era pets and new drug pipeline
MicroStrategy Incorporated